Furthermore, TREM2 agonistic antibody AL002, have beeninvestigated for the treatment of Alzheimer’s disease and have demonstratedfavorable safety and tolerability profiles in phase I clinical trials, suggestingthat pharmacological modulation of the TREM2-PtdSer pathway could potentially berepurposed to promote hematoma resolution following ICH [42]. This evidence concerns the gene TREM2 and hematoma.